Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0003 0.00 (0.00%)
As of 08/17/2026 01:37 PM Eastern
Compare

SMFL vs. GNCA, PXMD, ARDS, GNCAQ, and SCPS

Should you buy Smart for Life stock or one of its competitors? Smart for Life's main competitors and comparable companies include Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), Genocea Biosciences (GNCAQ), and Scopus BioPharma (SCPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Smart for Life compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Smart for Life has higher revenue and earnings than Genocea Biosciences. Smart for Life is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Smart for Life N/A N/A N/A

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, meaning that its stock price is 1,410% more volatile than the broader market.

In the previous week, Smart for Life had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Smart for Life Neutral

Summary

Smart for Life beats Genocea Biosciences on 9 of the 10 factors compared between the two stocks.

How does Smart for Life compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

PaxMedica has higher earnings, but lower revenue than Smart for Life. PaxMedica is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, meaning that its stock price is 1,410% more volatile than the broader market.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Smart for Life had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for PaxMedica. PaxMedica's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Smart for Life Neutral

Smart for Life's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Smart for Life N/A N/A N/A

Summary

Smart for Life beats PaxMedica on 8 of the 10 factors compared between the two stocks.

How does Smart for Life compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Smart for Life has higher revenue and earnings than Aridis Pharmaceuticals. Smart for Life is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.31N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Aridis Pharmaceuticals has a beta of 49.66, suggesting that its stock price is 4,866% more volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, suggesting that its stock price is 1,410% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Smart for Life N/A N/A N/A

In the previous week, Aridis Pharmaceuticals and Aridis Pharmaceuticals both had 1 articles in the media. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aridis Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Smart for Life
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Smart for Life beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Genocea Biosciences?

Smart for Life (NASDAQ:SMFL) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Genocea Biosciences has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

In the previous week, Smart for Life had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Genocea Biosciences. Smart for Life's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Genocea Biosciences Neutral

28.4% of Smart for Life shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Smart for Life has a beta of 15.1, meaning that its share price is 1,410% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Genocea Biosciences N/A N/A N/A

Summary

Smart for Life beats Genocea Biosciences on 6 of the 6 factors compared between the two stocks.

How does Smart for Life compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Smart for Life N/A N/A N/A

Scopus BioPharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, Smart for Life had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Smart for Life Neutral

Scopus BioPharma has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.1, indicating that its share price is 1,410% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Smart for Life beats Scopus BioPharma on 5 of the 6 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SMFL vs. The Competition

Export
MetricSmart for LifePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2K$11.94B$7.06B$13.09B
Dividend YieldN/A2.69%2.56%10.63%
P/E Ratio0.00782.05270.2624.33
Price / Sales0.00959.69680.01125.40
Price / CashN/A15.1628.8838.50
Price / Book0.0010.4611.196.43
Net Income-$22.68M$2.81B$3.46B$348.18M
7 Day PerformanceN/A0.39%0.82%-0.08%
1 Month PerformanceN/A0.66%2.52%1.47%
1 Year PerformanceN/A8.05%26.78%21.05%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
flat		N/A-88.5%$2K$11.11MN/A110
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/A+250.0%$6KN/AN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+0.0%$5KN/A0.0030
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 8/19/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel